Cerevel Therapeutics Holdings CERE 深 沪
已收盘 08-01 16:00:00 美东时间
44.96
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 44.96
- 总市值 818.27万
- 52周最高 44.99
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 19.59
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 46.161
- 量 比 0
- 振 幅 0.00%
- 历史最低 9.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options A clas...
2025-05-31 22:15
快讯 | Cerevel Therapeutics Holdings Inc重申之前发出的2024全年摊薄后每股收益指导区间为10.71-10.91美元。
Cerevel Therapeutics Holdings Inc - Reaffirms Previously Issued 2024 Full-Year ...
2024-08-01 20:24
Cerevel gains as AbbVie says it expects deal to close soon (update)
Update 9:45am: Updates shares, adds more AbbVie comments on timing of close. Cerevel Therapeutics (NASDAQ:CERE) rose 2% after AbbVie (NYSE:ABBV) said it expects its planned acquisition to close soon. ...
2024-07-25 21:44
Cerevel Therapeutics seesaws amid FTC notice on closed door meeting
Cerevel Therapeutics (NASDAQ:CERE) quickly swung between gains and losses amid a notice from the Federal Trade Commission of an upcoming meeting. Cerevel shares ticked higher by 0.7% after earlier sli...
2024-06-14 01:54
Catalyst Watch: Apple's WWDC, Tesla's annual meeting, Fed's dot plot, and GameStop volatility
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - June 10 Vol...
2024-06-08 03:00
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
2024-06-05 01:36
艾伯维(ABBV.US)收购的Cerevel(CERE.US)达成帕金森病药物晚期阶段主要目标
Cerevel Therapeutics周四宣布，其每日一次的帕金森病口服候选药物tavapadon在一项作为联合疗法的关键性三期试验中达成主要目标。
2024-04-18 21:25
AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug
AbbVie’s (NYSE:ABBV) buyout target, Cerevel Therapeutics (NASDAQ:CERE), announced Thursday that its oral, once-daily Parkinson’s disease candidate, tavapadon, reached its main goals in a pivotal Phase...
2024-04-18 19:00
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease.
2024-03-25 23:27
